GDBP gains license to monoclonal antibody for China
GANSU, China—Privately held Apexigen and Gansu Duyiwei Biological Pharmaceutical (GDBP) have announced a collaboration that will provide GDBP with an exclusive license to develop and commercialize APX004 in China. APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases. Under the agreement, GDBP will be solely responsible for researching, developing and commercializing APX004 in China, while Apexigen will collaborate with GDBP to advance the development program and will retain all rights to the compound outside of China. Apexigen will receive an upfront payment, regulatory milestone payments and a royalty, though no specific financial details were disclosed. Zhiping Duan, CEO of GDBP, said the deal will become a developmental milestone for the company.